

Completion of Security Purchase Plan

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart based pain assessment and monitoring application, is pleased to announce the results of its security purchase plan offer (SPP or SPP Offer), as announced to the ASX on Wednesday, 14 February 2024.

The SPP raised \$2,522,500, PainChek will issue 100,378,167 new fully paid ordinary shares (FPOS), which will rank equally with existing FPOS from their date of issue, under the SPP Offer. The new FPOS will be issued at \$0.0251 per FPOS.

The proceeds of the SPP will be applied:

- USA market entry and commercialisation (Adult App) including the submission of US FDA De Novo regulatory clearance application (targeting De Novo clearance for Q3 CY2024);
- Accelerate commercial growth of Adult App in International markets;
- Commence commercialisation of the Infant App;
- Strengthening of the Company’s cyber security;
- Completion of technology upgrade; and
- Working capital requirements and costs of the Offer

Issue of the new FPOS will occur on Monday, 11 March 2024 and the new FPOS are expected to commence trading on Tuesday, 12 March 2024. Holding statements will be dispatched to successful applicants on 12 March 2024. Refunds in the form of a direct credit deposit or cheque for unsuccessful applications will be made from 12 March 2024.

The announcement has been approved for release by the Board of Directors.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,000 aged care facilities, with more than 4,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>